What peptides will the FDA advisory panel review in July 2026?

The Pharmacy Compounding Advisory Committee will review seven peptides on July 23-24: BPC-157, TB-500 (Thymosin Beta-4), KPV, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. Five additional peptides will be reviewed at a second meeting before February 2027.

Does this mean BPC-157 is legal to compound now?

No. The Category 2 restrictions remain in effect until the FDA formally removes these substances from the list. The July meeting is advisory — even if the panel votes to recommend adding them back, the FDA must still draft and finalize rules before compounding can legally resume.

Why did Hims & Hers stock surge 12% on this news?

Hims & Hers has aggressively expanded into compounded peptide services. If the FDA allows compounding pharmacies to legally produce these seven peptides, Hims stands to benefit directly from expanded access to these popular treatments through its telehealth platform.

Can RFK Jr. appoint the panelists who will vote on peptides?

Yes. The PCAC currently has multiple vacancies, and Kennedy as HHS Secretary has authority to fill them before the July meeting. Many advisers and staff who oversaw the original Biden-era restrictions no longer work for the agency, making the composition of the panel a critical variable.

Which peptides will stay restricted even after this review?

Approximately 5 of the 19 peptides restricted under the Biden administration are expected to remain in Category 2: Melanotan II (cardiovascular and melanoma concerns), LL-37/Cathelicidin (limited human data), GHRP-2 (cortisol/prolactin risks), and PEG-MGF (unknown long-term effects).

How can I submit a public comment on the peptide review?

Public comments can be submitted through regulations.gov under Docket No. FDA-2025-N-6895. The comment period is open until July 22, 2026. Comments submitted by July 9 will be provided directly to the Committee members before the meeting.

PeptideKey News

FDA Schedules July Peptide Panel — BPC-157 Under Review

FDA announces July 23-24 advisory panel to review 7 peptides including BPC-157 and TB-500 for return to legal compounding. Hims surges 12%.

This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.